Lipid nanoparticle compositions and related methods
Dendritic-cell-tropic LNPs with serine-based helper-lipids and saturated phosphatidylserine enhance mRNA transfection and lymph-node delivery, addressing the limitations of conventional LNPs by improving antigen presentation and reducing inflammation.
WO2026097065A1PCT designated stage Publication Date: 2026-05-07THE RGT UNIV OF MICHIGAN
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- THE RGT UNIV OF MICHIGAN
- Filing Date
- 2025-11-04
- Publication Date
- 2026-05-07
Smart Images
Figure US2025053923_07052026_PF_FP_ABST
Abstract
The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.
Need to check novelty before this filing date? Find Prior Art